Magnetic Resonance Imaging in the Differential Diagnosis of Multiple Sclerosis and Other Demyelinating Diseases
https://doi.org/10.20862/0042-4676-2019-100-4-229-236
Abstract
The diagnosis of multiple sclerosis (MS) is quite complicated, which is associated with its clinical features and the lack of unique confirmatory tests. Magnetic resonance imaging (MRI) is one of the ways to confirm the diagnosis and also makes it possible to establish a differential diagnosis with other demyelinating diseases and to exclude diseases that mimic MS. This review presents not only MRI criteria for MS and other diseases similar to the MRI pattern, but also additional clinical and laboratory data, without which it is impossible to make a correct diagnosis.
Keywords
multiple sclerosis,
magnetic resonance imaging,
differential diagnosis,
non-tumor multifocal changes in the brain
Supporting agencies: The study had no sponsorship.
About the Authors
I. A. Krotenkova
Research Center of Neurology
Russian Federation
Cand. Med. Sc., Researcher
Russian Federation
Cand. Med. Sc., Researcher
V. V. Bryukhov
Research Center of Neurology
Russian Federation
Cand. Med. Sc., Senior Researcher
Russian Federation
Cand. Med. Sc., Senior Researcher
R. N. Konovalov
Research Center of Neurology
Russian Federation
Cand. Med. Sc., Leading Researcher
Russian Federation
Cand. Med. Sc., Leading Researcher
M. N. Zakharova
Research Center of Neurology
Russian Federation
Dr. Med. Sc., Head of 6 Neurology Department
Russian Federation
Dr. Med. Sc., Head of 6 Neurology Department
M. V. Krotenkova
Research Center of Neurology
Russian Federation
Dr. Med. Sc., Head of Radiology Department
Russian Federation
Dr. Med. Sc., Head of Radiology Department
References
1. Chen J.J., Carletti F., Young V., Mckean D., Quaghebeur G. MRI differential diagnosis of suspected multiple sclerosis. Clin. Radiol. 2016; 71 (9): 815–27. DOI: 10.1016/j.crad.2016.05.010
2. Bryukhov V.V., Kulikova S.N., Krotenkova I.A., Krotenkova M.V., Peresedova A.V. Magnetic resonance imaging in multiple sclerosis. Medical Visualization. 2014; 2: 10–21 (in Russ.).
3. Krotenkova I.A., Bryukhov V.V., Peresedova A.V., Krotenkova M.V. Atrophy of the central nervous system in multiple sclerosis: MRI-morphometry results. S.S. Korsakov Journal of Neurology and Psychiatry. 2014; 114 (10-2): 50–6 (in Russ.).
4. Thompson A.J., Banwell B.L., Barkhof F., Carroll W.M., Coetzee T., Comi G. et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018; 17(2): 162–73. DOI: 10.1016/S1474-4422(17)30470-2
5. Charil A., Yousry T.A., Rovaris M., Barkhof F., De Stefano N., Fazekas F., Filippi M. MRI and the diagnosis of multiple sclerosis: expanding the concept of “no better explanation”. Lancet Neurol. 2006; 5 (10): 841–52. DOI: 10.1016/s1474-4422(06)70572-5
6. Miller D., Weinshenker B., Filippi M., Banwell B., Cohen J., Freedman M., Polman C. Differential diagnosis of suspected multiple sclerosis: a consensus approach. Multiple Scler. J. 2008; 14 (9): 1157–74. DOI: 10.1177/1352458508096878
7. Solomon A.J., Klein E.P., Bourdette D. “Undiagnosing” multiple sclerosis: the challenge of misdiagnosis in MS. Neurology. 2012; 78 (24): 1986–91. DOI: 10.1212/ wnl.0b013e318259e1b2
8. Rovira A`., Wattjes M.P., Tintoré M., Tur C., Yousry T.A., Montalban X. MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis – clinical implementation in the diagnostic process. Nature Rev. Neurol. 2015; 11 (8): 471–82. DOI: 10.1038/nrneurol.2015.106
9. Vogl T.J., Friebe C.E., Balzer T., Mack M.G., Steiner S., Schedel H. et al. Diagnosis of cerebral metastasis with standard dose gadobutrol vs. a high dose protocol. Intraindividual evaluation of a phase II high dose study. Radiologe. 1995;35 (8): 508–16.
10. Rohrer M., Bauer H., Mintorovitch J., Requardt M., Weinmann H.-J. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest. Radiol. 2005; 40 (11): 715–24. DOI:10.1097/01.rli.0000184756.66360.d3
11. Uysal E., Erturk S.M., Yildirim H., Seleker F., Basak M. Sensitivity of immediate and delayed gadolinium-enhanced MRI after injection of 0.5 M and 1.0 M gadolinium chelates for detecting multiple sclerosis lesions. Am. J. Roentgen.2007; 188 (3): 697–702. DOI: 10.2214/ajr.05.2212
12. Benner T., Reimer P., Erb G., Schuierer G., Heiland S., Fischer C. et al. Cerebral MR perfusion imaging: first clinical application of a 1 M gadolinium chelate (Gadovist 1.0) in a double-blinded randomized dose-finding study. J. Magn. Res. Imag. 2000; 12 (3): 371–80. DOI: 10.1002/1522-2586(200009)12
13. Rovira A., Auger C., Huerga E., Corral J.F., Mitjana R., Sastre-Garriga J., Montalban X. Cumulative dose of macrocyclic gadolinium-based contrast agent improves detection of enhancing lesions in patients with multiple sclerosis. Am. J. Neuroradiol. 2017; 38 (8): 1486–93. DOI: 10.3174/ajnr.a5253
14. Bryukhov V.V., Krotenkova I.A., Morozova S.N., Krotenkova M.V. Standartization of MRI studies in multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry.2016; 116 (10-2): 27–34 (in Russ.). DOI: 10.17116/ jnevro201611610227-34
15. ESUR 8.1. European Society of Urogenital Radiology Guidelines on contrast agents. Version 8.1. 2012. European Society of Urogenital Radiology website; 2012. Available at: http://www.esur.org/guidelines/
16. Pohl D., Alper G., Van Haren K., Kornberg A.J., Lucchinetti C.F., Tenembaum S., Belman A.L. Acute disseminated encephalomyelitis. Neurology. 2016; 87 (9; Suppl. 2): S38–S45. DOI: 10.1212/wnl.0000000000002825
17. Callen D.J.A., Shroff M.M., Branson H.M., Li D.K., Lotze T., Stephens D., Banwell B.L. Role of MRI in the differentiation of ADEM from MS in children. Neurology. 2008; 72 (11): 968–73. DOI: 10.1212/01.wnl.0000338630.20412.45
18. Koelman D.L.H., Benkeser D.C., Klein J.P., Mateen F.J. Acute disseminated encephalomyelitis: prognostic value of early follow-up brain MRI. J. Neurol. 2017; 264 (8): 1754–62. DOI: 10.1007/s00415-017-8563-3
19. Misu T., Sato D.K., Nakashima I., Fujihara K. MOG-IgG serological status matters in paediatric ADEM. J. Neurol. Neurosurg. Psych. 2014; 86 (3): 242. DOI: 10.1136/jnnp-2014-308723
20. Sa M., Thornton R., Chong W.K., Kaliakatsos M., Hacohen Y. Paediatric MOG antibody – associated ADEM with complex movement disorder: a case report. Multiple Scler. J. 2018;25 (1): 125–8. DOI: 10.1177/1352458518786074
21. Vitt J.R., Brown E.G., Chow D.S., Josephson S.A. Confirmed case of levamisole-associated multifocal inflammatory leukoencephalopathy in a cocaine user. J. Neuroimmunol. 2017; 305: 128–30. DOI: 10.1016/j.jneuroim.2017.01.018
22. Franco D.A., Greenberg H.S. 5-FU multifocal inflammatory leukoencephalopathy and dihydropyrimidine dehydrogenase deficiency. Neurology. 2001; 56 (1): 110–2. DOI:10.1212/wnl.56.1.110
23. Shavlovskaya О.А. Levamisol-induced leukoencephalopathy: clinical case. Annals of Clinical and Experimental Neurology. 2018; 12 (3): 75–80 (in Russ.). DOI: 10.25692/ ACEN.2018.3.10
24. Chen T.C., Hinton D.R., Leichman L., Atkinson R.D., Apuzzo M.L.J., Couldwell W.T. Multifocal inflammatory leukoencephalopathy associated with levamisole and 5-fluorouracil. Neurosurgery. 1994; 35 (6): 1138–43. DOI:10.1097/00006123-199412000-00019
25. Wingerchuk B.G., Wingerchuk D.M. Neuromyelitis optica spectrum disorders. Oxford Med. Online. 2016. DOI: 10.1093/ med/9780199341016.003.0023
26. Schreiner T.L., Bennett J.L. Neuromyelitis Optica. Oxford Med. Online. 2017. DOI: 10.1093/med/9780199937837.003.0088
27. Filippi M., Rocca M.A. MR imaging of Devic’s neuromyelitis optica. Neurol. Sc. 2004; 25 (S4): s371–3. DOI:10.1007/s10072-004-0344-y
Review
For citations:
Krotenkova I.A., Bryukhov V.V., Konovalov R.N., Zakharova M.N., Krotenkova M.V. Magnetic Resonance Imaging in the Differential Diagnosis of Multiple Sclerosis and Other Demyelinating Diseases. Journal of radiology and nuclear medicine. 2019;100(4):229-236. (In Russ.) https://doi.org/10.20862/0042-4676-2019-100-4-229-236
Views:
3625
Email this article 